<DOC>
	<DOCNO>NCT00395538</DOCNO>
	<brief_summary>Hypoparathyroidism rare condition associate low level parathyroid hormone ( PTH ) blood . Hypoparathyroidism genetic show childhood , occur later life . If occurs later , usually due damage removal parathyroid glands neck surgery . PTH help control amount calcium blood , kidney , bone . Low level calcium blood cause person feel sick . It cause cramp tingle hand , foot , part body . A low blood calcium cause fainting seizure . The standard treatment hypoparathyroidism form vitamin D ( calcitriol ) calcium supplement . Keeping normal blood level calcium difficult . Sometimes much calcium urine even calcium level blood low . High calcium kidney urine cause problem calcium deposit kidney ( nephrocalcinosis ) kidney stone . High level calcium kidney may keep kidney function normally . Treatment PTH replace hormone miss . Your disease may better control PTH calcium calcitriol . Researchers NIH conduct prior study establish synthetic human parathyroid hormone 1-34 ( HPTH ) treatment hypoparathyroidism . Other study show PTH may improve calcium level blood urine . The primary purpose research study evaluate effect synthetic human parathyroid hormone 1-34 ( HPTH ) replacement therapy bone adult teenager hypoparathyroidism . The study take 5 ( Omega ) year complete require 12 inpatient visit National Institutes Health Clinical Center Bethesda , MD . The first visit help study team decide whether eligible . This visit last 2 3 day . After take calcium calcitriol 1 - 7 month return NIH Clinical Center baseline visit . The baseline visit visit start PTH ; also undergo bone biopsy visit . The baseline visit may last 7 10 day . You take PTH twice day 5 year . You ask return NIH clinical center every 6 month 10 follow-up visit . During one follow-up visit , second bone biopsy take hip . That second biopsy do 1 year , 2 year , 4 year take PTH ; researcher assign time second biopsy randomly . You ask go local laboratory blood urine test follow visit . At first blood test occur least week . Later , need go local laboratory blood test least month urine test every 3 month . The local laboratory visit follow-up visit NIH Clinical Center help study team determine whether HPTH treatment control hypoparathyroidism .</brief_summary>
	<brief_title>Effects PTH Replacement Bone Hypoparathyroidism</brief_title>
	<detailed_description>Objectives The primary objective study evaluate skeletal effect hormone replacement therapy HPTH hypoparathyroidism . Study Population This study enroll 69 subject physician-diagnosed hypoparathyroidism. &lt; TAB &gt; Design This study treat hypoparathyroid individual synthetic human PTH 1-34 ( HPTH ) 5 year , periodically assess skeletal change biochemical marker iliac-crest bone biopsy , allow ultrastructural , cellular , molecular analysis . With respect HPTH treatment , study single group , within-subjects , repeat measure treatment trial . With respect bone biopsy analysis , design parallel group design subject allocate one 3 biopsy follow-up time : 1 , 2 4 year initiation HPTH therapy . Post-baseline biopsy time randomly assign ( 1:1.2:1.4 , respectively ) subject , stratify gender menopausal status , relevant . Changes baseline ( time 0 ) 1 , 2 4-years compare . Subjects conventional therapy former version protocol also randomize new study design . In contrast new subject , whose biopsy perform end conventional care run-in period , pre-conventional care biopsy use baseline subject enter new design conventional care old protocol . Because known certainty effect duration time conventional therapy biopsy result , randomization also stratify status prior study participation . The subject HPTH therapy time protocol redesign follow separate group protocol . Outcome Measures Primary : Changes static dynamic bone histomorphometry 1 year , 2 year , 4 year HPTH therapy . Primary outcome measurement include : - Mineralized perimeter - Bone formation rate - Cortical width - Cortical area - Osteoid width - Osteoid perimeter - Mineral apposition rate Secondary : Changes bone mineralization density distribution 1 , 2 4 year HPTH therapy . The specific outcome measure include : - Spectral calcium-mean - Calcium-peak - Calcium-width Changes baseline assess follow outcome : - Biochemical marker bone metabolism : osteocalcin , bone-specific alkaline phosphatase , collagen cross-linked N-telopeptide . - Serum urine calcium ; 1,25-OH2-Vitamin D - Bone density assess DXA quantitative CT - Nephrocalcinosis ultrasound CT - Fatigue Symptom Inventory - 6-Minute Walk Test - SF-36 Health Survey Tertiary : Changes blood chemistry FGF23 , renal mineral handling , PTH sensitivity initiation HPTH , include : - Serum albumin , calcium , phosphorus , magnesium , sodium , potassium , chloride , Total CO2 , creatinine , glucose , urea nitrogen , FGF23 - Urine cAMP , creatinine , phosphorus , calcium , pH</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age eligibility screening : 1 . Premeopausal woman : age 18 45 year , 2 . Postmenopausal woman : age great equal 53 year 70 year 5 year since last menses . For woman without uterus , subject must clinical history menopause least 5 year FSH great 30 U/L . 3 . Men : age 18 70 year , 2 . Physiciandiagnosed hypoparathyroidism least 1year duration , confirm medical record review . The investigator confirm diagnosis screen visit time subject must intact PTH &lt; 30 pg/mL . EXCLUSION CRITERIA : 1 . Moderate severe hepatic disease define hepatic transaminase ( ALT AST ) &gt; 2 time upper limit normal 2 . Severe renal insufficiency define calculated GFR &lt; 25 mL/min/1.73 ( 2 ) , use CKDEPI equation ( 15 ) . 3 . Allergy intolerance tetracycline antibiotic 4 . Pregnant lactate plan become pregnant course study . ( Women able get pregnant must agree use effective form birth control study. ) . 5 . Perimenopausal define menses 6 month 5 year FSH &gt; 20 U/L screen and/or baseline visits.. 6 . Chronic disease might affect mineral metabolism diabetes , celiac disease , Crohn disease , Cushing syndrome , adrenal insufficiency 7 . Concurrent treatment dos thyroid hormone intend suppress thyroid stimulate hormone assay detection limit persistent thyroid cancer 8 . History skeletal disease unrelated hypoparathyroidism , osteoporosis low bone density ( define DXA ZScore &lt; 2 subject Tscore &lt; 2 subject great equal 20 year old ) , osteosarcoma , Paget disease , alkaline phosphatase &gt; 1.5 time upper limit normal , metastatic bone disease 9 . History retinoblastoma LiFraumeni syndrome 10 . History treatment bisphosphonates , calcitonin , tamoxifen , selectiveestrogen receptor modulators , direct skeletal irradiation 11 . Use oral intravenous corticosteroid estrogen replacement therapy 3 week within last 6 month 12 . Use depot medroxyprogesterone contraception within past 12 month 13 . Chronic inadequate biochemical control conventional therapy and/or calcium infusion dependent 14 . Seizure disorder require antiepileptic medication 15 . Treatment PTH 2 week continuously time , prior study entry 16 . Any cognitive impairment limit subject ability comply , independently assistance legally authorize representative , protocol procedure . 17 . Open epiphysis determine Xray hand wrist subject &lt; 21 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 14, 2017</verification_date>
	<keyword>Parathyroid</keyword>
	<keyword>Bone Biopsy</keyword>
	<keyword>Calcium-Sensing Receptor</keyword>
	<keyword>Bone Density</keyword>
	<keyword>Bone Turnover</keyword>
	<keyword>Hypoparathyroidism</keyword>
</DOC>